Pappalardi, Melissa B.

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Chan-Penebre, E., Kuplast, K. G., Majer, C. R., Boriack-Sjodin, P. A., Wigle, T. J., Johnston, L. D., Rioux, N., Munchhof, M. J., Jin, L., Jacques, S. L., et al. (2015) · Nature Chemical Biology

Cancer-related gene regulationProtein Degradation and Inhibitors

Cited by 569

HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy

Jiang, Q., Braun, D. A., Clauser, K. R., Ramesh, V., Shirole, N. H., Duke-Cohan, J. E., Nabilsi, N., Kramer, N. J., Forman, C., Lippincott, I. E., et al. (2025) · Cell

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 68

Abstract 2994: Discovery of selective, noncovalent small molecule inhibitors of DNMT1 as an alternative to traditional DNA hypomethylating agents

Pappalardi, M. B., Cockerill, M., Handler, J. L., Stowell, A., Keenan, K., Sherk, C. S., Minthorn, E. A., McHugh, C. F., Burt, C., Wong, K., et al. (2018) · Cancer Research

Epigenetics and DNA MethylationHistone Deacetylase Inhibitors Research

Cited by 9

A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation

Ge, A. Y., Arab, A., Dai, R., Navickas, A., Fish, L., Garcia, K., Asgharian, H., Goudreau, J., Lee, S., Keenan, K., et al. (2024) · Scientific Reports

Epigenetics and DNA MethylationAcute Myeloid Leukemia Research

Cited by 4